



Directions for use (to be completed by Eye Care Professional):

Dear Pharmacist,

Please help this individual select any over-the-counter brand of preservative-free artificial tears eye drops. The individual is taking a prescription-only medication called belantamab mafodotin[▼], which may cause dry eyes and eye irritation among other eye-related side effects.

SEE REVERSE SIDE FOR DIRECTIONS FOR USE

This patient is on treatment with belantamab mafodotin, known to cause serious ocular effects (including keratopathy).

See reverse for more information

Myeloma Doctor Phone Number:

Myeloma Doctor Name:

Emergency Contact Phone Number:

Emergency Contact Name:

Drug Indication:

Drug Name and Dose:

Patient Name:

Please be sure to present this card to your myeloma doctor during your regular follow-up visits.

Primary Doctor Name:

Primary Doctor Phone Number:

Eye Care Professional Name:

Eye Care Professional Phone Number:

Additional Information:

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the product package leaflet. You can also report side effects directly to HPRA Pharmacovigilance on their website: www.hpra.ie. By reporting side effects, you can help provide more information on the safety of this medicine.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting side effects you may get.

GSK

Electronic Certificate

Version: 1 . 0

Document Number: NP-IE-MMU-CRD-250001

Document Name: Belamaf Ireland | RMP Patient Wallet Card | Feb 2026

Country: Ireland

Product: MULTIPLE MYELOMA UNBRANDED

Type: Non-promotional content

It is certified that this material has been examined in its final electronic form and is believed to be in accordance with the requirements of S.I. No. 541 of 2007 (Medicinal Products [Control of Advertising] Regulation), the GSK Code of practice for promotion and scientific engagement (STD_344428), and the IPHA Code of Practice for the Pharmaceutical Industry. The material is a fair and truthful presentation of the facts about the product(s), it supports the rational use of medicines and is not inconsistent with the relevant marketing authorisation(s) and Summary of Product Characteristics.

Role	Signature
Michael Dillon - Medical (michael.v.dillon@gsk.com)	It is approved that this material has been examined and is believed to be in accordance with the relevant Code of Practice and any other relevant regulations, policies and SOPs. Date: 19-Feb-2026 11:17:47 GMT+0000
Priya Amlani - Pharmacovigilance (priya.m.amlani@gsk.com)	It is approved that this material has been examined and is believed to be in accordance with the relevant Code of Practice and any other relevant regulations, policies and SOPs. Date: 19-Feb-2026 15:26:26 GMT+0000